Patient factors influencing dermal filler complications: Prevention, assessment, and treatment

Clinical, Cosmetic and Investigational Dermatology

Volumn 8, Issue , 2015, Pages 205-214

  De Boulle, Koenraad ^a   Heydenrych, Izolda ^b  

^a Aalst Dermatology Group   (Belgium)

^b Cape Town Cosmetic Dermatology Centre   (South Africa)

Author keywords

Assessment; Complications; Dermal fillers; Patient factors; Prevention; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ACRYLAMIDE DERIVATIVE; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; BOTULINUM TOXIN; CETIRIZINE; CIPROFLOXACIN; CLARITHROMYCIN; CLOPIDOGREL; FLUOROURACIL; HISTAMINE H1 RECEPTOR ANTAGONIST; HYALURONIDASE; HYDROXYAPATITE; IBUPROFEN; IMIQUIMOD; LIDOCAINE; LORATADINE; LOW MOLECULAR WEIGHT HEPARIN; METHACRYLIC ACID; METHOTREXATE; METHYLPREDNISOLONE; PENTOXIFYLLINE; PREDNISOLONE; PROPRANOLOL; RETINOID; SILDENAFIL; SILICONE DERIVATIVE; STEROID; UNINDEXED DRUG; VANCOMYCIN;

ALLERGIC REACTION; ANGIONEUROTIC EDEMA; ARTERY OCCLUSION; ARTICLE; BLISTER; BLOOD VESSEL OCCLUSION; CLINICAL ASSESSMENT; CRYOTHERAPY; DERMATOLOGICAL PROCEDURE; ERYTHEMA; ESTHETIC SURGERY; EVIDENCE BASED PRACTICE; GRANULOMATOUS SKIN DISEASE; HEMATOMA; HUMAN; INFRARED RADIATION; INJECTABLE IMPLANT; OUTCOME ASSESSMENT; PATIENT EDUCATION; PATIENT SATISFACTION; PATIENT SELECTION; PLASTIC SURGEON; PRACTICE GUIDELINE; PUSTULE; SKIN INFECTION; SKIN NODULE; SYSTEMATIC REVIEW; TREATMENT CONTRAINDICATION; URTICARIA; WOUND CARE;

EID: 84930626701     PISSN: None     EISSN: 11787015     Source Type: Journal    
DOI: 10.2147/CCID.S80446     Document Type: Article

References (49)

1. Requena L, Requena C, Christensen L, Zimmermann US, Kutzner H, Cerroni L. Adverse reactions to injectable soft tissue fillers. J Am Acad Dermatol. 2010;64:1-34.
2. De Boulle K. Management of complications after implantation of fillers. J Cosmet Dermatol. 2004;3:2-15.
3. Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Invest Dermatol. 2013;6: 295-316.
4. Sperling B, Bachmann F, Hartmann V, Erdmann R, Wiest L, Rzany B. The current state of treatment of adverse reactions to injectable fillers. Dermatol Surg. 2010;36:1895-1904.
5. Vedamurthy M, Vedamurthy A, Nischal KC. Dermal fillers: do’s and dont’s. J Cutan Aesthet Surg. 2010;3:11-15.
6. Bailey SH, Cohen JL, Kenkel JM. Etiology, prevention and treatment of dermal filler complications. Aesthetic Surg J. 2011;31:110-121.
7. de Bree R, Middelweerd MJ, van der Waal I. Severe granulomatous inflammatory response induced by injection of polyacrylamide gel into the facial tissue. Arch Facial Plast Surg. 2004;6(3):204-206.
8. Micheels P, Sarazin D, Besses S, Sundaram H, Flynn TC. A blanching technique for intradermal injection of the hyaluronic acid Belotero. Plast Reconstruct Surg. 2013;132(4 Suppl 2):59S-68S.
9. Lemperle G, Rullan PP, Gautier-Hazan N. Avoiding and treating dermal filler complications. Plast Reconstr Surg. 2006;118(3 Suppl):92S-107S.
10. Lafaille P, Benedetto A. Fillers: contraindications, side effects and precautions. J Cutan Aesth Surg. 2010;3:16-19.
11. Narins RS, Jewell M, Rubin M, Cohen J, Strobos J. Clinical conference: management of rare events following dermal fillers -focal necrosis and angry red bumps. Dermatol Surg. 2006;32:426-434.
12. Narins RS, Coleman WP, Glogau RG. Recommendations and treatment options for nodules and other filler complications. Dermatol Surg. 2009;35:1667-1671.
13. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol. 2007;7(10):1271-1285.
14. Lowe NJ, Maxwell CA, Patnaik R. Adverse reactions to dermal fillers: review. Dermatol Surg. 2005;31:1616-1625.
15. Alam M, Gladstone H, Kramer EM, et al; American Society for Dermatologic Surgery. ASDS guidelines of care: injectable fillers. Dermatol Surg. 2008;34:S115-S148.
16. Levy LL, Emer JJ. Complications of minimally invasive cosmetic procedures: prevention and management. J Cutan Aesthet Surg. 2012;5:121-132.
17. Kraft CT, Bellile E, Baker SR, Kim JC, Moyer JS. Anticoagulant complications in facial plastic and reconstructive surgery. JAMA Facial Plast Surg. 2014. Epub ahead of print.
18. Brown DG, Wilkerson EC, Love WE. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. J Am Acad Dermatol. 2014;72(3):524-534.
19. Gladstone HB, Cohen JL. Adverse events when injecting facial fillers. Semin Cutan Med Surg. 2007;26(1):34-39.
20. Glogau RG, Kane MA. Effect of injection techniques on the rate of local adverse events in patients implanted with non-animal hyaluronic acid gel fillers. Dermatol Surg. 2008;34:S105-S109.
21. Carruthers J, Glogau R, Blitzer A; Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies -consensus recommendations. Plast Reconstruc Surg. 2008;121:5-30.
22. Hermesch CB, Hilton TJ, Biesbrock AR, et al. Perioperative use of 0.12% chlorhexidine gluconate for the prevention of alveolar osteitis: efficacy and risk factor analysis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:381-387.
23. Baima J, Isaac Z. Clean versus sterile technique for common joint infections: a review from the physiatry perspective. Curr Rev Musculoskeletal Med. 2008;1:88-91.
24. Kim YS, Choi DY, Gil YC, Hu KS, Tansatit T, Kim HJ. The anatomical origin and course of the angular artery regarding its clinical implications. Dermatol Surg. 2014;40(10):1070-1076.
25. Yang HM, Lee JG, Hu KS, et al. New anatomical insights on the course and branching patterns of the facial artery: clinical implications of injectable treatments to the nasolabial fold and nasojugal groove. Plast Reconstr Surg. 2014;133(5):1077-1082.
26. Kim DW, Yoon ES, Ji YH, Park SH, Lee BI, Dhong ES. Vascular complications of hyaluronic acid fillers and the role of hyaluronidase in management. J Plast Reconstr Aesthet Surg. 2011;64:1590-1595.
27. Sclafani AP, Fagien S. Treatment of injectable soft tissue filler complications. Dermatol Surg. 2009;35:1672-1680.
28. Cohen JL. Understanding¸ avoiding and managing dermal filler complications. Dermatol Surg. 2008;34(Suppl 1):S92-S99.
29. Zeichner JA, Cohen JL. Using blunt-tipped cannulas in specific regions for soft-tissue augmentation. J Drugs Dermatol. 2012;11:40-41.
30. Cassuto D. Blunt-tipped microcannulas for filler injection: an ethical duty? J Drugs Dermatol. 2012;11:S42.
31. Dayan SH, Arkins JP, Brindise R. Soft tissue fillers and biofilm. Fac Plast Surg. 2011;27:23-28.
32. Hirsch RJ, Cohen JL, Carruthers JD. Successful management of an unusual presentation of impending necrosis following a hyaluronic acid injection embolus and a proposed algorithm for management with hyaluronidase. Dermatol Surg. 2007;33:357-360.
33. Peter S, Mennel S. Retinal branch artery occlusion following injection of hyaluronic acid (Restylane). Clin Experiment Ophthalmol. 2006;34(4):363-364.
34. Hwang YH, Hwang JH, Kim JS. Branch retinal artery occlusion after periocular dermal filler injection. Retin Case Brief Rep. 2008;2: 338-341.
35. Lazzeri D, Agostini T, Figus M, Nardi M, Pantaloni M, Lazzeri S. Blindness following cosmetic injections of the face. Plas Reconstruct Surg. 2012;129:995-1012.
36. Kleydman K, Cohen JL, Marmur E. Nitroglycerin: a review of its use in the treatment of vascular occlusion after soft tissue augmentation. Dermatol Surg. 2012;38:1889-1897.
37. Ozturk CN, Li Y, Tung R, Parker L, Piliang MP, Zins JE. Complications following injection of soft tissue fillers. Aesth Surg J. 2013;33: 862-877.
38. Brody HM. Relevance of cosmeceuticals to the dermatologic surgeon. Dermatol Surg. 2005;31:796-798.
39. Feighery C, McCoy EP, Johnson PB, Armstrong DKB. Delayed hypersensitivity to hyaluronidase (Hyalse™) used during cataract surgery. Contact Dermatitis. 2007;57:343.
40. Reidl MA, Casillas AM. Adverse drug reactions: types and treatment options. Am Fam Physician. 2003;68:1781-1790.
41. Sánchez O, Rodríguez-Sureda V, Domínguez C, et al. Study of biomaterial-induced macrophage activation, cell-mediated immune response and molecular oxidative damage in patients with dermal bioimplants. Immunology. 2012;217(1):44-53.
42. Moody BR, Sengelmann RD. Topical tacrolimus in the treatment of bovine collagen hypersensitivity. Dermatol Surg. 2001;27:789-791.
43. Christensen LH. Host tissue interaction, fate, and risks of degradable and non-degradable gel fillers. Dermatol Surg. 2009;35:1612-1619.
44. Pecharki D, Petersen FC, Scheie AA. Role of hyaluronidase in Streptococcus Iintermedius biofilm. Microbiology. 2008;154: 932-938.
45. Nyhlen A, Ljungberg B, Nilsson-Ehle I, Odenholt I. Bactericidal effect of combinations of antibiotic and antineoplastic agents against Staphylococcus aureus and Escherichia coli. Chemotherapy. 2002;48:71-77.
46. Cassuto D, Marangoni O, De Santis G, Christensen L. Advanced laser techniques for filler-induced complications. Dermatol Surg. 2009;35:1689-1695.
47. Cassuto D, Sundaram H. A problem-oriented approach to nodular complications from hyaluronic acid and calcium hydroxyapatite fillers: classification and recommendations for treatment. Plast Reconstr Surg. 2013;132:48S-58S.
48. Ledon JA, Savas JA, Yang S, Franca K, Camacho I, Nouri K. Inflammatory nodules following soft tissue filler use: a review of causative agents, pathology and treatment options. Am J Clin Dermatol. 2013;14:401-411.
49. Lemperle G, Gauthier-Hazan N. Foreign body granulomas after all injectable fillers: part 2. Treatment options. Plast Reconstr Surg. 2009;123:1864-1873.